All In Biotech

Free tool

FAERS Monitor: Sodium Phenylacetate and Sodium Benzoate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215025 or its brand name (Sodium Phenylacetate and Sodium Benzoate, Sodium Benzoate, Sodium Phenylacetate). Reports on generic versions are filed under their own applications.

Reports

9

Serious

7

78% of reports

Hospitalization

3

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective5
  • hyperglycaemia2
  • ammonia decreased1
  • anion gap increased1
  • blood lactic acid increased1
  • brain oedema1
  • cerebral infarction1
  • drug ineffective for unapproved indication1
  • maternal exposure during pregnancy1
  • mycoplasma test positive1
  • off label use1
  • therapy non-responder1

Reports by year received

View as table
YearReports
20183
20211
20223
20241
20251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,150 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ammonia decreased130381.24723.17,497
mycoplasma test positive115492.42424.43,847
anion gap increased11749.7275.5436
blood lactic acid increased1443.769.9110
brain oedema1185.129.245
hyperglycaemia2128.337.8142
cerebral infarction195.715.123
therapy non-responder152.08.212
drug ineffective for unapproved indication142.66.710
maternal exposure during pregnancy126.24.16
drug ineffectiveSignal58.94.929
off label use12.70.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.